Yiming Liu

Partner at Cooley

Speaker

Yiming Liu is the partner in charge of Cooley's Shanghai office. He advises life sciences and healthcare companies, throughout their lifecycles and often in strategic transactions, including IPOs, cross-border M&A, venture capital financings, joint ventures, and licensing and collaboration agreements.

Yiming has practiced corporate law in New York, Hong Kong and Shanghai, and he previously received academic training and advanced degrees in molecular, cellular and developmental biology and health services administration. Yiming leverages his broad experience and technical background to help clients achieve their desired results. In recent years, Yiming advised numerous life sciences and healthcare companies in IPOs as well as M&A and various other cross-border transactions, including Innovent Biologics, Akesobio, RemeGen, Keymed Biosciences, Brii Biosciences, Jacobio Pharmaceuticals, Asymchem Laboratories, and ImmuneOnco Biopharmaceuticals.

Yiming was named a “Growth Driver” by China Business Law Journal (CBLJ) and included in CBLJ’s 2023-2024 “The A-List” elite lawyers in China. He has been ranked by Thomson Reuters, Asian Legal Business (ALB) among "2022 ALB China Top 15 Capital Markets Lawyers" and among "2022 ALB China Top 15 Rising Lawyers". In addition, he has been recognized by International Financial Law Review (IFLR) as a "Rising Star Partner for M&A in China (Foreign Firm)" in the IFLR1000 2023 Asia Pacific rankings, and he has been ranked as a “Key Lawyer for Life Sciences and Healthcare in China (Foreign Firm)” in the Legal 500 2024 Asia Pacific rankings.